Figure 2 Schema for the phase II Randomized Observation versus

Slides:

Advertisements

Similar presentations

Prostate Cancer Cancer: Cancer is a term used for diseases in which abnormal cells divide without control and are able to invade other tissues. Cancer.

Advertisements

Breast SSG: SABR and Oligometastatic Disease

Compassionate People World Class Care

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Nat. Rev. Urol. doi: /nrurol

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 2 Recruitment of experts to the Delphi study

Figure 1 Concept of the therapeutic index

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Risk-adapted and response-adapted

Figure 1 Cellular processes involved in cancer development

Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Urol. doi: /nrurol

Figure 3 Semantic model of the active surveillance (AS) timeline

Nat. Rev. Urol. doi: /nrurol

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Figure 2 Peptide vaccination using TAA-derived long peptides

Figure 2 Representative images from a right radical

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 3 Proportion of patients for whom NEDA

Figure 1 Key elements of the proposed modified Delphi study

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 5 The biological effects of charged particles

Figure 1 The development process of the Asian

Figure 1 Differences in bladder cancer between genders

therapy and to block androgen action

Figure 13 Proposed management of bladder cancer with variant histology

Figure 3 Treatment algorithm for adult infertile men with varicoceles

Figure 3 Algorithm for the determination of the clinical

Figure 4 Dosimetric comparison of LDR‑BT versus HDR‑BT

Nat. Rev. Urol. doi: /nrurol

Figure 1 The dynamic nature of resistance mechanisms can be

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 6 Image sequence demonstrating coronal cuts on MRI

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Differences in renal cell carcinoma (RCC) between genders

Radiation Therapy for Prostate Cancer

Figure 3 Template for standard pelvic lymphadenectomy

Nat. Rev. Urol. doi: /nrurol

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Logistical requirements for autologous

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 The evolution of brachytherapy for prostate cancer

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Nat. Rev. Urol. doi: /nrurol

Figure 4 The grey zone between active

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

CORE: A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy (SBRT)) in Extracranial oligometastases (CRUK/14/038)

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Presentation transcript:

Figure 2 Schema for the phase II Randomized Observation versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE) trial Figure 2 | Schema for the phase II Randomized Observation versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE) trial. Men with metachronous hormone-naive oligometastatic disease will be enrolled and dynamically randomized to the schema as shown. AP, alkaline phosphatase; CTCs, circulating tumour cells; ctDNA, cell-free circulating tumour DNA; LDH, lactate dehydrogenase; PBMC, peripheral blood mononuclear cells; SABR, stereotactic ablative radiation; SBRT, stereotactic radiation therapy; T, serum testosterone. ORIOLE is sponsored by the National Cancer Institute (NCI) 1U01CA183031 and a Movember-PCF Challenge Award. Tosoian, J. J. et al. (2016) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations Nat. Rev. Urol. doi:10.1038/nrurol.2016.175